Selective Targeting of TNF Receptors as a Novel Therapeutic Approach
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Tumor necrosis factor (TNF) is a central regulator of immunity. Due to its dominant pro-inflammatory effects, drugs that neutralize TNF were developed and are clinically used to treat inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, despite their clinical success the use of anti-TNF drugs is limited, in part due to unwanted, severe side effects and in some diseases its use even is contraindicative. With gaining knowledge about the signaling mechanisms of TNF and the differential role of the two TNF receptors (TNFR), alternative therapeutic concepts based on receptor selective intervention have led to the development of novel protein therapeutics targeting TNFR1 with antagonists and TNFR2 with agonists. These antibodies and bio-engineered ligands are currently in preclinical and early clinical stages of development. Preclinical data obtained in different disease models show that selective targeting of TNFRs has therapeutic potential and may be superior to global TNF blockade in several disease indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 3×
“PKB/Akt then is recruited to the plasma membrane by direct binding to PIP3 through its pleckstrin-homology (PH) domains (Lawlor and Alessi, 2001).”
BackgroundInflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“…a 26 kDa type II transmembrane protein that assembles into a homotrimeric molecule (tmTNF) (Kriegler et al., 1988) that can be proteolytically cleavage by the matrix metalloproteases (MMP) TNFα-converting enzyme (TACE/ADAM17) resulting in soluble TNF homotrimers (sTNF; 51 kDa) (Black et al., 1997).”
BackgroundSignalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · cited 1×
“Keywords: TNF, TNFR1, TNFR2, therapy, inflammation, tissue regeneration INTRODUCTION Tumor necrosis factor (TNF) is a key regulatory component of the immune system that regulates innate and adaptive immunity and contributes to initiation and maintenance of inflammation (Aggarwal, 2003).”
BackgroundInduction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
Micheau, O., & Tschopp, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00521-x · Cited by 2,738
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234 · cited 1×
“Vice versa, in various diet-induced or genetic NAFLD models, TNF- or TNFR-deficient mice showed improved insulin sensitivity and less pronounced liver steatosis and fibrosis (Uysal et al., 1997, 1998; Tomita et al., 2006).”
BackgroundRegulated necrosis: the expanding network of non-apoptotic cell death pathways
Berghe, T. V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., & Vandenabeele, P. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3737 · Cited by 1,735 · cited 1×
“Phosphorylation of MLKL results in a conformational change, recruitment to the plasma membrane and execution of necroptosis via membrane permeabilization (Vanden Berghe et al., 2014; Grootjans et al., 2017).”
Background
Cited by
TNF in the liver: targeting a central player in inflammation
Tiegs, G., & Horst, A. K. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00910-2 · Cited by 224
TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer’s Disease
Pillai, J. A., Bebek, G., Khrestian, M., Bena, J., Bergmann, C. C., Bush, W. S., Leverenz, J. B., & Bekris, L. M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638922 · Cited by 29
Droessler, L., Cornelius, V., Markov, A. G., & Amasheh, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168746 · Cited by 18
Specific S100 Proteins Bind Tumor Necrosis Factor and Inhibit Its Activity
Kazakov, A. S., Zemskova, M. Y., Rystsov, G. K., Vologzhannikova, A. A., Deryusheva, E. I., Rastrygina, V. A., Sokolov, A. S., Permyakova, M. E., Litus, E. A., Uversky, V. N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415956 · Cited by 12
Alterations in bone fracture healing associated with TNFRSF signaling pathways
Dong, Y., Zhou, H., Alhaskawi, A., Wang, Z., Lai, J., Abdullah Ezzi, S. H., Kota, V. G., Abdulla Hasan Abdulla, M. H., Sun, Z., & Lu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905535 · Cited by 9
Metadata
- Authors
- Fischer, R., Kontermann, R. E., & Pfizenmaier, K.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-26
- Volume
- 8
- Pages
- 401-401
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3031816528
- Cited by
- 241
- References
- 21
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.